Close Menu

Correction: Dec 5, 2003

Premium

An RNAi News report on Nov. 14 described the Aventis Cambridge Genomics Center’s efforts to acquire a set of siRNAs against 5,000 druggable genes from Dharmacon, quoting the center’s RNAi platform head Dorre Grueneberg.

Grueneberg said at the time that the center was planning on buying the siRNA set from Dharmacon for $285,000. Gruenberg, however, said this week that Qiagen is the seller of the set, not Dharmacon.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.